National Health Investors (NHI) Q2 2026 Earnings Report

The call presents a largely positive strategic and financial picture driven by the transformative NHC sale (material gain and strong liquidity), rapid expansion of the SHOP platform (137% increase to ~$850M) and significant SHOP NOI growth in aggregate (188.5% YoY). Management enhancements (new COO, CFO) and a dividend increase further reinforce confidence. However, near-term operational and earnings challenges persist: same-store SHOP performance showed YoY weakness, normalized FFO declined modestly, G&A and interest costs rose, and some SHOP properties face occupancy and operational pressures. The acquisition market is competitive with compressed yields, creating underwriting pressure. Overall, the positives (balance sheet strength, liquidity, SHOP scale-up, sequential operational improvement and active pipeline) outweigh the near-term headwinds, but execution will be critical to realize the anticipated long-term benefits.

NHI left its full‑year SHOP outlook unchanged, maintaining same‑store SHOP NOI growth guidance of 1%–3% (which management said implies roughly 8%–9% growth in H2), and reiterated that newer SHOP investments should drive high‑single to low‑double‑digit NOI growth; Q2 SHOP NOI rose 188.5% YoY to $11.0M, SHOP investment has increased 137% to ≈$850M (24% of the company), year‑to‑date investments were $237.2M at a 7.7% average yield (>$212M in SHOP), with ~$127.3M of signed LOIs (initial yield 6.8%, 6.5% after maintenance CapEx) and ~ $420M under evaluation. Key financial and balance‑sheet metrics cited: Q2 net income per share $1.15 (+45.6%), NAREIT/normalized FFO $1.19 (flat / -2.5%), FAD $61.6M (+5.8%), cash rental income +2.8% YoY, Q2 G&A $8.8M (+44%) with cash G&A guidance up low‑teens YoY, EBITDARM coverages (12 months ended 3/31/26) senior housing 1.62 and SNF 2.66, net debt/adjusted EBITDA 4.1x (policy 3.5–4.5x), available liquidity ≈$792.4M ($262M excess revolver + $500M ATM/cash), July NHC sale proceeds $560M (expected Q3 gain ≈$541.6M) with ~$221M used for 1031 replacements and ~$334M held for reinvestment, and a dividend increase of $0.02 to $0.94 per share.